Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VCYT vs NEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: VCYT 4 – 2 NEO Matrix Metrics: VCYT 7 – 3 NEO

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over NeoGenomics, Inc. (NEO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas NEO carries 35.0/100 (SELL) at $15.41 (N/M Forward P/E, -5.5% operating margin).

  • Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile NEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VCYT vs NEO
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79
NEO NASDAQ
NeoGenomics, Inc.
Services-Testing Laboratories
$15.41
-3.81% 1D
Market Cap $2.1B
TTM Revenue $788M
Forward P/E N/M
Beta / 30D Vol 1.22β · 47% Vol
Unified Composite Score
35.0 / 100 SELL
Tech 21.0 Fund 44.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 38
RSI-14: 37.8 · SMA20: $16.85 · SMA50: $17.51

6-Pillar Scorecard Institutional Category Breakdown (VCYT 4 – 2 NEO)

Columns: Metric · VCYT · NEO
1. Valuation Multiples VCYT
Forward P/E 15.3x N/M
Trailing P/E 15.8x N/M
PEG Ratio N/M 2.09x
EV / Revenue 3.1x 3.0x
2. Growth & Scale NEO
Revenue Growth (YoY) +15.1% +11.4%
Earnings Growth (YoY) +58.3% +130.6%
TTM Revenue (USD) $582M $788M
Market Cap $2.0B $2.1B
3. Profitability & Quality VCYT
Gross Margin 74.2% 44.8%
Operating Margin 15.0% -5.5%
Net Profit Margin 21.8% -4.1%
Return on Equity (ROE) 9.4% -3.9%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) $162M -$29M
Cash Flow Margin 27.8% -3.6%
Net Cash / Leverage $159M Net Cash $310M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEO
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 197.3% (47th %ile) 100.0% (14th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.12x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity 59.2% of Rev ($344M) 50.3% of Rev ($396M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VCYT (7) vs NEO (3)
Institutional Metric VCYT NEO Criterion Row Edge
Market Capitalization
Scale
$2.0B $2.1B Larger Scale NEO
Trailing P/E Ratio
Valuation
15.8x N/M Lower Multiple VCYT
Forward P/E Ratio
Valuation
15.3x N/M Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+15.1% +11.4% Higher Growth VCYT
Operating Margin (TTM)
Profitability
15.0% -5.5% Higher Margin VCYT
Net Profit Margin
Profitability
21.8% -4.1% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
9.4% -3.9% Higher ROE VCYT
52-Week Range Position
Momentum
5% ($22–$61) 64% ($7–$20) Stronger Trend NEO
Beta / 30D Volatility
Risk Regime
3.01β · 199% Vol 1.22β · 47% Vol Lower Realized Risk NEO
Unified Institutional Score
Composite Signal
49.1 / 100 (HOLD) 35.0 / 100 (SELL) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$582M $788M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 44.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 2.09x PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$162M ($159M Net Cash) -$29M ($310M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NEO +36.87 pp
VCYT: -44.32% · NEO: -7.45%
3M Horizon NEO +37.9 pp
VCYT: -40.98% · NEO: -3.08%
6M Horizon NEO +126.25 pp
VCYT: -42.14% · NEO: +84.11%
1Y Horizon NEO +93.73 pp
VCYT: -39.78% · NEO: +53.95%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VCYT Revenue NEO Revenue VCYT Op. Margin NEO Op. Margin Margin Leader
FY2018 $90M $280M -24.2% 3.6% NEO
FY2019 $120M $410M -12.6% 3.2% NEO
FY2020 $120M $440M -30.1% -3.1% NEO
FY2021 $220M $480M -37.3% -24.5% NEO
FY2022 $300M $510M -13.9% -30.9% VCYT
FY2023 $360M $590M -23.8% -18.2% NEO
FY2024 $450M $660M 3.6% -13.9% VCYT
FY2025 $520M $730M 11.2% -15.9% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NEO CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.0%
IV Percentile 14th %ile
Put/Call OI Skew 0.12x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published
NEO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.1B market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment 50.3% of Rev ($396M)
90D Engineering Disclosures 0 Published

Investor FAQ VCYT vs NEO Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over NeoGenomics, Inc. (NEO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas NEO carries 35.0/100 (SELL) at $15.41 (N/M Forward P/E, -5.5% operating margin). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile NEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NEO leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with NEO at +11.4% YoY revenue growth and +130.6% YoY earnings growth on $788M TTM revenue (44.8% gross margin, -5.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while NEO shifted +160.7%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 50.3% of Rev ($396M) (0 disclosures) for NEO.

VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas NEO trades at N/M Forward P/E, N/M Trailing P/E, 2.09x PEG, and 3.0x EV/Revenue (-3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus NEO (-3.9% ROE) capital efficiency.

In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, NEO carries 100.0% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.22β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.